ETFIQData as of Nov 19, 2026. · etfiq.com/funds/ffox

FFOX Fact Sheet: FundX Future Fund Opportunities ETF

Share
$24.70
close, Nov 20, 2026

Over the year to Nov 19, 2026, FFOX returned −2.7% in total and charged 1.02% a year.

1-year total return
−5.2%
to Nov 20, 2026
Expense ratio
1.02%
a year

Growth of $10,000, 1 year

FFOX $9,731 −2.7% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−13.0%
3 months−18.5%
Year to date−9.4%
1 year−5.2%
Since launch−0.4%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Halozyme Therapeutics Inc3.20%
Guardant Health Inc3.11%
Carpenter Technology Corp2.25%
Mercury Systems Inc2.19%
BWX Technologies Inc2.10%
Ionis Pharmaceuticals Inc2.06%
Ciena Corp2.06%
Natera Inc2.02%
Ligand Pharmaceuticals Inc1.93%
Advanced Drainage Systems Inc1.90%

FFOX top ten by weight, 22.8% of the fund, of its 73 equity positions, from the holdings filed for Jun 30, 2026.

Facts

Equity fund · First traded Jun 10, 2025 · Benchmark Its own holdings, as of Jun 30, 2026; its prospectus names no index it tracks

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, FFOX Fact Sheet: FundX Future Fund Opportunities ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/ffox/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ffox.